-
Je něco špatně v tomto záznamu ?
Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis
Y. Li, Y. Tan, G. Xia, J. Shuai
Jazyk angličtina Země Spojené státy americké
Typ dokumentu metaanalýza, systematický přehled, časopisecké články
- MeSH
- HDL-cholesterol MeSH
- inzulinová rezistence * MeSH
- lidé MeSH
- prebiotika MeSH
- probiotika * terapeutické užití MeSH
- synbiotika * MeSH
- syndrom polycystických ovarií * metabolismus MeSH
- triglyceridy MeSH
- Check Tag
- lidé MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- metaanalýza MeSH
- systematický přehled MeSH
This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of probiotics, prebiotics, and synbiotics on insulin resistance (IR), lipid profiles, anthropometric indices, and C-reactive protein (CRP) level for polycystic ovary syndrome (PCOS). We searched 8 databases from their inception until 1st October, 2020. The effect sizes were expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Subgroup analyses were undertaken for further identification of effects of probiotics, prebiotics, and synbiotics, based on the following aspects: (1) type of intervention (probiotics, prebiotics, or synbiotics); (2) study duration (≥ 12 weeks or < 12 weeks); (3) number of probiotic strains (multi strains or single strain); (4) probiotic dose (≥ 2 × 108 colony-forming units [CFU] or < 2 × 108 CFU). A total of 17 eligible RCTs with 1049 participants were included. Results showed that probiotic, prebiotic, and synbiotic intake decreased fasting plasma glucose (SMD, -1.35; 95% CI, -2.22 to -0.49; p = 0.002), fasting insulin (SMD, -0.68; 95% CI, -1.08 to -0.27; p = 0.001), homeostatic model of assessment for IR (SMD, -0.73; 95% CI, -1.15 to -0.31; p = 0.001), triglycerides (SMD, -0.85; 95% CI, -1.59 to -0.11; p = 0.024), total cholesterol (SMD, -1.09; 95% CI, -1.98 to -0.21; p = 0.015), low-density lipoprotein cholesterol (SMD, -0.84; 95% CI, -1.64 to -0.03; p = 0.041), very-low-density lipoprotein cholesterol (SMD, -0.44; 95% CI, -0.70 to -0.18; p = 0.001), and increased quantitative insulin sensitivity check index (SMD, 2.00; 95% CI, - 0.79 to 3.22; p = 0.001). However, probiotic, prebiotic, and synbiotic supplements did not affect anthropometric indices, high-density lipoprotein cholesterol, and CRP levels. Subgroup analysis showed that probiotic or prebiotic might be the optimal choice for ameliorating IR or lipid profiles, respectively. Additionally, the effect was positively related to courses and therapeutical dose. Overall, the meta-analysis demonstrates that probiotic, prebiotic, or synbiotic administration is an effective and safe intervention for modifying IR and lipid profiles.
Affiliated Hospital of Nanjing University of Chinese Medicine Nanjing China
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23004849
- 003
- CZ-PrNML
- 005
- 20230425171745.0
- 007
- ta
- 008
- 230418s2023 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/10408398.2021.1951155 $2 doi
- 035 __
- $a (PubMed)34287081
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Li, Yuling $u Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China $u Nanjing University of Chinese Medicine, Nanjing, China
- 245 10
- $a Effects of probiotics, prebiotics, and synbiotics on polycystic ovary syndrome: a systematic review and meta-analysis / $c Y. Li, Y. Tan, G. Xia, J. Shuai
- 520 9_
- $a This meta-analysis of randomized controlled trials (RCTs) was performed to summarize the effects of probiotics, prebiotics, and synbiotics on insulin resistance (IR), lipid profiles, anthropometric indices, and C-reactive protein (CRP) level for polycystic ovary syndrome (PCOS). We searched 8 databases from their inception until 1st October, 2020. The effect sizes were expressed as standardized mean difference (SMD) with 95% confidence intervals (95% CI). Subgroup analyses were undertaken for further identification of effects of probiotics, prebiotics, and synbiotics, based on the following aspects: (1) type of intervention (probiotics, prebiotics, or synbiotics); (2) study duration (≥ 12 weeks or < 12 weeks); (3) number of probiotic strains (multi strains or single strain); (4) probiotic dose (≥ 2 × 108 colony-forming units [CFU] or < 2 × 108 CFU). A total of 17 eligible RCTs with 1049 participants were included. Results showed that probiotic, prebiotic, and synbiotic intake decreased fasting plasma glucose (SMD, -1.35; 95% CI, -2.22 to -0.49; p = 0.002), fasting insulin (SMD, -0.68; 95% CI, -1.08 to -0.27; p = 0.001), homeostatic model of assessment for IR (SMD, -0.73; 95% CI, -1.15 to -0.31; p = 0.001), triglycerides (SMD, -0.85; 95% CI, -1.59 to -0.11; p = 0.024), total cholesterol (SMD, -1.09; 95% CI, -1.98 to -0.21; p = 0.015), low-density lipoprotein cholesterol (SMD, -0.84; 95% CI, -1.64 to -0.03; p = 0.041), very-low-density lipoprotein cholesterol (SMD, -0.44; 95% CI, -0.70 to -0.18; p = 0.001), and increased quantitative insulin sensitivity check index (SMD, 2.00; 95% CI, - 0.79 to 3.22; p = 0.001). However, probiotic, prebiotic, and synbiotic supplements did not affect anthropometric indices, high-density lipoprotein cholesterol, and CRP levels. Subgroup analysis showed that probiotic or prebiotic might be the optimal choice for ameliorating IR or lipid profiles, respectively. Additionally, the effect was positively related to courses and therapeutical dose. Overall, the meta-analysis demonstrates that probiotic, prebiotic, or synbiotic administration is an effective and safe intervention for modifying IR and lipid profiles.
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a synbiotika $7 D058616
- 650 _2
- $a prebiotika $7 D056692
- 650 12
- $a syndrom polycystických ovarií $x metabolismus $7 D011085
- 650 12
- $a probiotika $x terapeutické užití $7 D019936
- 650 _2
- $a triglyceridy $7 D014280
- 650 12
- $a inzulinová rezistence $7 D007333
- 650 _2
- $a HDL-cholesterol $7 D008076
- 655 _2
- $a metaanalýza $7 D017418
- 655 _2
- $a systematický přehled $7 D000078182
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Tan, Yong $u Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China $u Nanjing University of Chinese Medicine, Nanjing, China
- 700 1_
- $a Xia, Guicheng $u Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China $u Nanjing University of Chinese Medicine, Nanjing, China
- 700 1_
- $a Shuai, Jiaqi $u Masaryk University, Brno, The Czech Republic
- 773 0_
- $w MED00001241 $t Critical reviews in food science and nutrition $x 1549-7852 $g Roč. 63, č. 4 (2023), s. 522-538
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34287081 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230418 $b ABA008
- 991 __
- $a 20230425171742 $b ABA008
- 999 __
- $a ok $b bmc $g 1925128 $s 1191058
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 63 $c 4 $d 522-538 $e 20210721 $i 1549-7852 $m Critical reviews in food science and nutriton $n Crit Rev Food Sci Nutr $x MED00001241
- LZP __
- $a Pubmed-20230418